<DOC>
	<DOC>NCT01330472</DOC>
	<brief_summary>Study to evaluate if Xanax sustained release tablets manufactured at two different sites provide similar drug levels in the blood.</brief_summary>
	<brief_title>An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites</brief_title>
	<detailed_description />
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 20 and 55 years, inclusive. An informed consent document signed and dated by the subject. Evidence or history of clinically significant abnormality. A positive urine drug screen. Subjects who are hypersensitive to alprazolam or related compounds.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Alprazolam</keyword>
	<keyword>Xanax</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Panic disorder with or without agoraphobia.</keyword>
</DOC>